NewLink Genetics to Present Data on Indoximod at American Society of Clinical Oncology (ASCO) Annual Meeting

On June 03, 2016 NewLink Genetics Corporation (NASDAQ:NLNK) reported that it will present two posters highlighting the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod, at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 5 in Chicago (Press release, NewLink Genetics, JUN 3, 2016, View Source [SID:1234512977]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s two abstracts at ASCO (Free ASCO Whitepaper) will highlight:

Abstract 3075: Updates on Phase 1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma;
Time: 8:00 AM to 11:30 AM
Date: Sunday, June 5, 2016
Poster Discussion Session: Developmental Therapeutics—Immunotherapy
Abstract 3020: Interim analysis on Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer.
Time: 8:00 AM to 11:30 AM
Date: Sunday, June 5, 2016
Poster Discussion Session: Developmental Therapeutics—Immunotherapy
About NewLink Genetics’ Indoleamine 2,3-Dioxygenase (IDO) Pathway Inhibitors

The indoleamine 2,3-dioxygenase (IDO) pathway regulates immune response by suppressing T cell function and enabling local tumor immune escape. NewLink Genetics is researching two IDO pathway inhibitors, GDC-0919 (in partnership with Genentech) and indoximod, both small-molecule product candidates that have the potential to disrupt mechanisms by which tumors evade the immune system. NewLink Genetics’ indoximod and GDC-0919 each have a distinct mechanism of action within the IDO pathway and are in Phase 1 or 2 clinical trials for a range of cancers, including breast cancer, melanoma, and other solid tumors.

About NewLink Genetics Corporation